AU2004303882A1 - 1-akan-2-ol substituted piperazine and piperidine compounds - Google Patents
1-akan-2-ol substituted piperazine and piperidine compounds Download PDFInfo
- Publication number
- AU2004303882A1 AU2004303882A1 AU2004303882A AU2004303882A AU2004303882A1 AU 2004303882 A1 AU2004303882 A1 AU 2004303882A1 AU 2004303882 A AU2004303882 A AU 2004303882A AU 2004303882 A AU2004303882 A AU 2004303882A AU 2004303882 A1 AU2004303882 A1 AU 2004303882A1
- Authority
- AU
- Australia
- Prior art keywords
- yloxy
- methylbenzothiazol
- piperazinyl
- propyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53125303P | 2003-12-18 | 2003-12-18 | |
| US60/531,253 | 2003-12-18 | ||
| PCT/US2004/042859 WO2005061470A1 (en) | 2003-12-18 | 2004-12-17 | 1-akan-2-ol substituted piperazine and piperidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2004303882A1 true AU2004303882A1 (en) | 2005-07-07 |
Family
ID=34710215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004303882A Abandoned AU2004303882A1 (en) | 2003-12-18 | 2004-12-17 | 1-akan-2-ol substituted piperazine and piperidine compounds |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US7115610B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1723129A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007514769A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20060124646A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004303882A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2550257A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005061470A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2550257A1 (en) * | 2003-12-18 | 2005-07-07 | Cv Therapeutics, Inc. | 1-akan-2-ol substituted piperazine and piperidine compounds |
| EP1829866A1 (en) * | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| BRPI0913291A2 (pt) | 2008-05-30 | 2019-01-15 | Takeda Pharmaceuticals Co | composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto |
| CN105175401A (zh) * | 2015-10-16 | 2015-12-23 | 北京康立生医药技术开发有限公司 | 一种依匹哌唑的制备方法 |
| EP4334293A1 (en) * | 2021-05-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2034305B (en) * | 1978-10-24 | 1982-12-22 | Wyeth John & Brother Ltd | Preparation of piperidine derivatives |
| DE3118881A1 (de) | 1980-09-29 | 1982-06-24 | Oltmanns Ziegel Und Kunststoffe Gmbh, 2905 Edewecht | "ziegel" |
| US4766125A (en) | 1981-06-23 | 1988-08-23 | Janssen Pharmaceutica N.V. | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia |
| US4558129A (en) | 1983-05-18 | 1985-12-10 | Syntex (U.S.A.) Inc. | Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade |
| US4567264A (en) | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| ES2177601T3 (es) | 1989-06-23 | 2002-12-16 | Syntex Llc | Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. . |
| HU209723B (en) * | 1990-10-31 | 1994-10-28 | Richter Gedeon Vegyeszet | Process for producing of piperazine derivatives |
| US5455045A (en) | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| NZ520780A (en) * | 2000-02-18 | 2006-04-28 | Cv Therapeutics Inc | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| AU2001238590A1 (en) | 2000-02-22 | 2001-09-03 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| NZ520782A (en) * | 2000-02-22 | 2004-03-26 | Cv Therapeutics Inc | Substituted piperazine compounds that are partial fatty acid oxidation inhibitors |
| US6451798B2 (en) | 2000-02-22 | 2002-09-17 | Cv Therapeutics, Inc. | Substituted alkyl piperazine derivatives |
| US6677336B2 (en) | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| US6552023B2 (en) | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
| IL151626A0 (en) * | 2000-04-07 | 2003-04-10 | Astrazeneca Ab | Quinazoline compounds |
| US6573264B1 (en) | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
| MXPA04000565A (es) * | 2001-07-19 | 2005-06-17 | Cv Therapeutics Inc | Compuestos de piperazina sustituidos y su uso como inhibidores de oxidacion de acidos grasos. |
| US7001909B2 (en) | 2001-07-19 | 2006-02-21 | Cv Therapeutics, Inc. | Substituted heterocyclic compounds |
| US6827946B2 (en) * | 2001-12-05 | 2004-12-07 | Collegium Pharmaceutical, Inc. | Compositions containing both sedative and non-sedative antihistamines |
| JP4171425B2 (ja) * | 2002-03-05 | 2008-10-22 | チバ ホールディング インコーポレーテッド | カラー写真記録材料 |
| US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
| CA2550257A1 (en) * | 2003-12-18 | 2005-07-07 | Cv Therapeutics, Inc. | 1-akan-2-ol substituted piperazine and piperidine compounds |
-
2004
- 2004-12-17 CA CA002550257A patent/CA2550257A1/en not_active Abandoned
- 2004-12-17 EP EP04814988A patent/EP1723129A1/en not_active Withdrawn
- 2004-12-17 US US11/015,915 patent/US7115610B2/en not_active Expired - Lifetime
- 2004-12-17 WO PCT/US2004/042859 patent/WO2005061470A1/en not_active Ceased
- 2004-12-17 KR KR1020067011920A patent/KR20060124646A/ko not_active Ceased
- 2004-12-17 JP JP2006545566A patent/JP2007514769A/ja active Pending
- 2004-12-17 AU AU2004303882A patent/AU2004303882A1/en not_active Abandoned
-
2006
- 2006-06-13 US US11/452,479 patent/US7262198B2/en not_active Expired - Lifetime
-
2007
- 2007-08-27 US US11/845,720 patent/US7452889B2/en not_active Expired - Lifetime
-
2008
- 2008-10-27 US US12/259,085 patent/US20090054457A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005061470A1 (en) | 2005-07-07 |
| US20060229317A1 (en) | 2006-10-12 |
| US7115610B2 (en) | 2006-10-03 |
| EP1723129A1 (en) | 2006-11-22 |
| US7452889B2 (en) | 2008-11-18 |
| US20080032993A1 (en) | 2008-02-07 |
| KR20060124646A (ko) | 2006-12-05 |
| JP2007514769A (ja) | 2007-06-07 |
| US7262198B2 (en) | 2007-08-28 |
| US20050197346A1 (en) | 2005-09-08 |
| CA2550257A1 (en) | 2005-07-07 |
| US20090054457A1 (en) | 2009-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ530705A (en) | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | |
| US7452889B2 (en) | Substituted heterocyclic compounds | |
| EP1567525B1 (en) | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | |
| EP1578737B1 (en) | Substituted heterocyclic compounds | |
| US20040186109A1 (en) | Substituted heterocyclic compounds | |
| EP1806346B1 (en) | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | |
| US7208496B2 (en) | Substituted heterocyclic compounds | |
| US7601721B2 (en) | Substituted heterocyclic compounds | |
| HK1083492B (en) | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | |
| HK1111683B (en) | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | |
| HK1085467B (en) | Substituted heterocyclic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |